(Q45283332)

11 December 2017

title

Individualization of immunosuppressive therapy. III. Sirolimus associated with a reduced incidence of malignancy (English)

1 reference

11 December 2017

1 reference

Yakupoglu YK

1

1 reference

11 December 2017

Buell JF

series ordinal

2

1 reference

11 December 2017

Woodle S

series ordinal

3

1 reference

11 December 2017

Kahan BD

series ordinal

4

1 reference

11 December 2017

language of work or name

English

0 references

publication date

1 March 2006

1 reference

Transplantation Proceedings

11 December 2017

published in

1 reference

11 December 2017

volume

38

1 reference

11 December 2017

issue

2

1 reference

11 December 2017

page(s)

358-361

1 reference

Risk of neoplasia in renal transplant patients.

11 December 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSPROCEED.2006.01.019

Cancer after kidney transplantation in the United States

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSPROCEED.2006.01.019

Lymphomas after solid organ transplantation: a collaborative transplant study report

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSPROCEED.2006.01.019

Cyclosporine induces cancer progression by a cell-autonomous mechanism.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSPROCEED.2006.01.019

Rapamune® (RAPA, rapamycin, sirolimus): mechanism of action immunosuppressive effect results from blockade of signal transduction and inhibition of cell cycle progression

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSPROCEED.2006.01.019

Rapamycin blocks tumor progression: unlinking immunosuppression from antitumor efficacy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSPROCEED.2006.01.019

Rapamycin inhibits primary and metastatic tumor growth by antiangiogenesis: involvement of vascular endothelial growth factor

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSPROCEED.2006.01.019

Low incidence of malignancy among sirolimus/cyclosporine-treated renal transplant recipients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSPROCEED.2006.01.019

Activity of rapamycin (AY-22,989) against transplanted tumors

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSPROCEED.2006.01.019

Rapamycin potentiates transforming growth factor beta-induced growth arrest in nontransformed, oncogene-transformed, and human cancer cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSPROCEED.2006.01.019

Sirolimus for Kaposi's sarcoma in renal-transplant recipients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSPROCEED.2006.01.019

A causal role for E-cadherin in the transition from adenoma to carcinoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSPROCEED.2006.01.019

Mechanism of action of rapamycin: new insights into the regulation of G1-phase progression in eukaryotic cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSPROCEED.2006.01.019

inferred from DOI database lookup

7 January 2021

based on heuristic

Studies on the mechanism of resistance to rapamycin in human cancer cells

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSPROCEED.2006.01.019

inferred from DOI database lookup

7 January 2021

based on heuristic

Identifiers

DOI

10.1016/J.TRANSPROCEED.2006.01.019

1 reference

11 December 2017

1 reference